GLSI / A Controversial Moonshot Stock Just Got a Lot More Interesting

Greenwich LifeSciences, Inc. is a one-man, one-asset shop. The asset, GP2, has produced excellent breast cancer data. more_horizontal

Greenwich Lifesciences Inc (NASDAQ: GLSI) shares are trading higher by 32.95% to $11.46 Tuesday afternoon after the FDA removed the clinical hold on t more_horizontal

Shares of Greenwich LifeSciences, Inc. are trading near their lowest levels since the stock exploded upward in December 2020 in what was an illustrati more_horizontal

When insiders buy a stock, you should take it as a sign that they think good news is about to come out. Here are three to watch closely. more_horizontal

When insiders buy a stock, you should take it as a sign that they think good news is about to come out. Here are three to watch closely. more_horizontal

When insiders buy a stock, you should take it as a sign that they think good news is about to come out. Here are three to watch closely. more_horizontal

Greenwich LifeSciences Inc (NASDAQ: GLSI) has published new GP2 Phase 2b trial data. The trial enrolled HER2 positive patients, who received a stand more_horizontal

Greenwich LifeSciences Inc (NASDAQ: GLSI) has published new GP2 Phase 2b trial data. The trial enrolled HER2 positive patients, who received a stand more_horizontal